Amnovis Expands US Operations to Serve Growing Demand for 3D Printed Medical Devices

Summary: Amnovis has expanded into the United States by acquiring Westconn Precision Technologies additive manufacturing business and establishing a hub near Warsaw, Indiana—the global center of orthopedic device manufacturing. The dual EU-US footprint allows medical device companies to qualify 3D printed medical devices across both jurisdictions under consistent quality systems, streamlining regulatory approval and supply chain resilience.

3D printed medical devices are gaining commercial momentum in the orthopedic sector, and a key European player is now positioning itself to serve the world largest medical device market directly. Amnovis, a Belgian additive manufacturing firm specializing in metal implants, has expanded into the United States by acquiring the AM business of Westconn Precision Technologies and establishing a new operations unit in North Webster, Indiana—just minutes from Warsaw, the city widely regarded as the global center of orthopedic device manufacturing.

Warsaw, Indiana: The World Orthopedic Capital

Warsaw is home to the headquarters of Zimmer Biomet and DePuy Synthes (a Johnson & Johnson MedTech company), two of the largest orthopedic implant companies globally. Over decades, the region has developed an interconnected ecosystem of OEMs, component suppliers, precision manufacturers, and specialized service providers. For Amnovis, setting up in this cluster means direct proximity to existing customers, experienced personnel, and the collaborative infrastructure that defines the medical device supply chain.

What Amnovis Brings to the US Market

In Europe, Amnovis has established itself as a vertically integrated partner for orthopedic innovation—covering everything from design for AM through production and regulatory submission. The company core capability is laser powder bed fusion (L-PBF) metal 3D printing, particularly for titanium spinal implants and other load-bearing structures featuring complex lattice geometries that conventional manufacturing cannot produce.

At its new US facility, Amnovis will replicate this model completely: metal AM printing, CNC machining, and electrical discharge machining (EDM) will all be available on-site, under the same quality management systems used at its Belgian headquarters. Chris Cook has been appointed General Manager of US Operations, with Jake Marasco joining as Account Manager.

Dual EU-US Manufacturing: A Regulatory and Commercial Advantage

The most strategically significant aspect of this expansion is Amnovis plan to operate redundant manufacturing capacity across its Belgian and US sites. For medical device companies, this addresses two longstanding challenges in the 3D printed medical devices space: regulatory fragmentation and supply chain concentration risk.

The US market represents a substantial share of the global medical device market—industry estimates commonly cite 30 to 50 percent of total global revenue for orthopedic devices. FDA clearance is widely respected internationally; many other national regulatory bodies use FDA approval as a reference point for their own review processes. By operating both sites under the same validated quality framework, Amnovis says it can help customers pursue simultaneous regulatory clearance in both the US and European Union—potentially reducing duplicate testing, shortening timelines, and simplifying ongoing supplier oversight.

This dual-regime model is uncommon among AM service bureaus, most of which operate from a single regional base. If a manufacturer can qualify parts with one partner across both jurisdictions, it eliminates the need to manage multiple supplier relationships and reduces the risk of qualification mismatches between sites.

Meeting Demand for Patient-Specific and Time-Critical Implants

Amnovis cited three primary drivers behind the acquisition: the size and accessibility of the US medical device market, rising demand for patient-specific and time-critical implant solutions, and the need for regionally distributed manufacturing capacity.

Patient-specific orthopedic implants—custom-manufactured to match an individual patient anatomy using CT or MRI imaging—are among the fastest-growing segments of medical AM. Producing these devices efficiently, at scale, and under multiple regulatory regimes requires both manufacturing flexibility and rigorous quality infrastructure. Amnovis combined printing and post-processing capability (CNC plus EDM) positions it to deliver fully finished implants rather than green-state parts that require additional outsourcing.

What This Means for the Additive Manufacturing Industry

The Amnovis expansion reflects a broader maturation in metal AM for medical devices. Early adopters used the technology primarily for prototyping and limited-volume commercial runs. Companies like Amnovis are now building the operational infrastructure—validated quality systems, regulatory expertise, multi-site redundancy—needed to support higher-volume commercial production at orthopedic scale.

For manufacturers evaluating 3D printed medical devices as a production option, the availability of a proven AM partner with both US FDA clearance capability and EU MDR coverage removes a meaningful barrier to adoption. Qualification work completed at one Amnovis site can often be leveraged at the other, potentially accelerating time to market in both regions simultaneously.

Amnovis is not the only AM service bureau targeting the orthopedic sector, but its industrialized operating model—consistent quality systems, redundant manufacturing footprint, full post-processing capability—represents a more mature service offering than most current market options.

Source: 3DPrint.com